CytomX Therapeutics Inc (NASDAQ:CTMX) has earned a consensus rating of “Buy” from the fourteen research firms that are currently covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation, eight have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $35.29.
Several research firms have recently commented on CTMX. Zacks Investment Research downgraded CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 10th. ValuEngine downgraded CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. BidaskClub downgraded CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. Finally, Citigroup began coverage on CytomX Therapeutics in a report on Friday, January 5th. They issued a “buy” rating and a $40.00 price objective for the company.
In other CytomX Therapeutics news, insider Sean A. Mccarthy sold 14,340 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $20.60, for a total transaction of $295,404.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Debanjan Ray sold 2,500 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $20.58, for a total value of $51,450.00. The disclosure for this sale can be found here. In the last three months, insiders sold 56,466 shares of company stock valued at $1,267,014. 4.70% of the stock is currently owned by insiders.
A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. lifted its holdings in CytomX Therapeutics by 28.5% during the 4th quarter. BlackRock Inc. now owns 2,646,599 shares of the biotechnology company’s stock valued at $55,870,000 after purchasing an additional 586,698 shares during the last quarter. Perceptive Advisors LLC lifted its holdings in CytomX Therapeutics by 79.1% during the 4th quarter. Perceptive Advisors LLC now owns 2,490,381 shares of the biotechnology company’s stock valued at $52,571,000 after purchasing an additional 1,100,000 shares during the last quarter. Vanguard Group Inc. lifted its holdings in CytomX Therapeutics by 12.2% during the 2nd quarter. Vanguard Group Inc. now owns 924,138 shares of the biotechnology company’s stock valued at $14,323,000 after purchasing an additional 100,607 shares during the last quarter. Millennium Management LLC lifted its holdings in CytomX Therapeutics by 34.0% during the 4th quarter. Millennium Management LLC now owns 837,415 shares of the biotechnology company’s stock valued at $17,678,000 after purchasing an additional 212,423 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in CytomX Therapeutics by 32.9% during the 4th quarter. Renaissance Technologies LLC now owns 715,100 shares of the biotechnology company’s stock valued at $15,096,000 after purchasing an additional 177,200 shares during the last quarter. 75.31% of the stock is owned by institutional investors and hedge funds.
CytomX Therapeutics (CTMX) traded up $0.62 during trading hours on Wednesday, reaching $29.22. The company’s stock had a trading volume of 219,115 shares, compared to its average volume of 299,423. CytomX Therapeutics has a 52-week low of $11.49 and a 52-week high of $29.26. The firm has a market cap of $1,150.00 and a P/E ratio of -18.61.
ILLEGAL ACTIVITY NOTICE: “Brokerages Set CytomX Therapeutics Inc (CTMX) Target Price at $35.29” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/24/brokerages-set-cytomx-therapeutics-inc-ctmx-target-price-at-35-29.html.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.